I-Mab (IMAB) announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board of Directors, effective as of August 22, 2025 and reiterated the appointment of independent director Dr. Sean Cao to the Board as of May 28, 2025. The Company also announced Lielie Zhang will be stepping down from the Board, effective as of August 20, 2025, with gratitude for his dedicated service. In addition, I-Mab announced the formation of a Research and Development Committee of the Board of Directors, R&D Committee, to be chaired by Dr. Robert Lenz, with Dr. Sean Cao and Dr. Sean Fu, Chief Executive Officer of I-Mab, as members. I-Mab will also expand its Scientific Advisory Board with the appointment of Dr. Ken Takeshita.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMAB:
- I-Mab’s Q2 2025: Clinical Progress and Financial Strength
- I-Mab price target raised to $6 from $5 at Needham
- I-MAB’s Positive Outlook: Buy Rating Backed by Financial Stability and Promising Clinical Developments
- I-Mab Reports Strong Financials and Clinical Progress in August 2025
- I-Mab reports Q2 EPS (3c), consensus (5c)